N,N-(Pentamethylene)-N'-(p-toluenesulfonyl)-2-chloroacetamidine | 121721-53-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N,N-(Pentamethylene)-N'-(p-toluenesulfonyl)-2-chloroacetamidine
• 英文别名: N-(2-chloro-1-piperidin-1-ylethylidene)-4-methylbenzenesulfonamide；N-(2-chloro-1-piperidine-1-ylethylidene)-4-methylphenyl sulfonamide
• CAS: 121721-53-7
• 化学式: C₁₄H₁₉ClN₂O₂S
• 分子量: 314.836
• InChiKey: OCSFUTAMZDLTEQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  58.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N,N-(Pentamethylene)-N'-(p-toluenesulfonyl)-2-chloroacetamidine 、 N-[[(2-methoxybenzyl)amino](imino)-methyl]thiourea 以yielded 12 mg of the desired product的产率得到1-[2-({imino[(2-methoxybenzyl)amino]methyl}amino)-1,3-thiazol-4(5H)-ylidene]piperidinium chloride
  参考文献：
  名称：

  Guanidine Compounds, and Use Thereof as Binding partners for 5-Ht5 Receptors

  摘要：

  本发明涉及通式I的胍化合物及其对应的对映异构体、顺反异构体和/或互变异构体，以及其药学上可接受的盐。本化合物进一步涉及胍化合物作为5-HT5受体的结合伴侣，用于治疗受5-HT5受体活性调节的疾病，特别是用于治疗神经退行性和神经精神障碍以及相关的症状、症候和功能障碍。

  公开号：

  US20070299074A1
• 作为产物：
  描述：

  N,N-(Pentamethylene)-2-chloroacetamidine Hydrochloride 、 对甲苯磺酰氯 在 sodium carbonate 作用下， 以 丙酮 为溶剂， 反应 0.25h， 以30%的产率得到N,N-(Pentamethylene)-N'-(p-toluenesulfonyl)-2-chloroacetamidine
  参考文献：
  名称：

  Abdelaal, Salma; Bauer, Ludwig, Journal of Heterocyclic Chemistry, 1988, vol. 25, p. 1849 - 1856

  摘要：

  DOI：

文献信息

• Guanidine Compounds, and Use Thereof as Binding partners for 5-Ht5 Receptors
  申请人：Netz Astrid

  公开号：US20070299074A1

  公开（公告）日：2007-12-27

  The present invention relates to guanidine compounds of the general formula I corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof. The present compound further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors for the treatment of diseases which are modulated by a 5-HT5 receptor activity, in particular for the treatment of neurodegenerative and neuropsychiatric disorders as well as the associated signs, symptoms and dysfunctions.

  本发明涉及通式I的胍化合物及其对应的对映异构体、顺反异构体和/或互变异构体，以及其药学上可接受的盐。本化合物进一步涉及胍化合物作为5-HT5受体的结合伴侣，用于治疗受5-HT5受体活性调节的疾病，特别是用于治疗神经退行性和神经精神障碍以及相关的症状、症候和功能障碍。
• GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS
  申请人：Netz Astrid

  公开号：US20110237589A1

  公开（公告）日：2011-09-29

  The present invention relates to guanidine compounds of the general formula I corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof. The present compound further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors for the treatment of diseases which are modulated by a 5-HT5 receptor activity, in particular for the treatment of neurodegenerative and neuropsychiatric disorders as well as the associated signs, symptoms and dysfunctions.

  本发明涉及一般式I的胍化合物，其对应的对映异构体、顺反异构体和/或互变异构体以及其药学上可接受的盐。本化合物进一步涉及将胍化合物用作5-HT5受体的结合伴侣，用于治疗由5-HT5受体活性调节的疾病，特别是用于治疗神经退行性和神经精神障碍以及相关的症状、症候和功能障碍。
• Abdelaal, Salma; Bauer, Ludwig, Journal of Heterocyclic Chemistry, 1988, vol. 25, p. 1849 - 1856
  作者：Abdelaal, Salma、Bauer, Ludwig

  DOI：——

  日期：——
• Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors
  申请人：Netz Astrid

  公开号：US08481576B2

  公开（公告）日：2013-07-09

  The present invention relates to guanidine compounds of the general formula I corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof. The present compound further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors for the treatment of diseases which are modulated by a 5-HT5 receptor activity, in particular for the treatment of neurodegenerative and neuropsychiatric disorders as well as the associated signs, symptoms and dysfunctions.

  本发明涉及一般式I的胍化合物及其对应的对映异构体、顺反异构体和/或互变异构体，以及其药学上可接受的盐。本化合物进一步涉及将胍化合物用作5-HT5受体的结合伴侣，用于治疗5-HT5受体活性调节的疾病，特别是用于治疗神经退行性和神经精神障碍以及相关的症状、症候和功能障碍。